抗纤溶药物对创伤性脑损伤后全身和脑部炎症的影响
本研究采用小鼠落锤模型诱导中度创伤性脑损伤,伤后10分钟分别给予氨甲环酸1、10、100 mg/kg,氨基己酸400 mg/kg,抑肽酶100 kIU/kg或等量生理盐水,于1、6、24小时检测血清和脑组织炎症因子,30天评估海马磷酸化tau。结果显示,氨甲环酸组脑内TNF-α、IL-6、MCP-1降低,但血清TNF-α和MIP-1α升高,磷酸化tau呈剂量依赖性降低;氨基己酸组脑IL-6在1小时升高,血清TNF-α、MIP-1α、MCP-1在24小时升高;抑肽酶组血清TNF-α、IL-6、MIP-1α升高而脑细胞因子无差异。作者认为氨甲环酸可能提供急性神经炎症保护,氨基己酸可能有害,抑肽酶可能增加全身炎症。
要点
- 小鼠中度TBI后10分钟给予氨甲环酸1、10、100 mg/kg,24小时脑内TNF-α、IL-6、MCP-1较生理盐水组降低。
- 氨甲环酸组血清TNF-α和MIP-1α在1至24小时较生理盐水组显著升高。
- 氨甲环酸组海马磷酸化tau在30天呈剂量依赖性显著降低。
- 氨基己酸400 mg/kg组脑IL-6在1小时升高,血清TNF-α、MIP-1α、MCP-1在24小时升高。
- 抑肽酶100 kIU/kg组血清TNF-α、IL-6、MIP-1α在1至24小时升高,脑细胞因子无差异。
适用人群与场景
- 小鼠落锤模型诱导的中度创伤性脑损伤。
处置流程与药物剂量
- 伤后10分钟(恢复后)给予氨甲环酸1、10或100 mg/kg,或氨基己酸400 mg/kg,或抑肽酶100 kIU/kg,或等量生理盐水。
- 于伤后1、6、24小时处死检测血清和脑组织神经元特异性烯醇化酶及炎症因子,30天评估海马磷酸化tau积累。
研究设计与关键结果
- 研究类型:小鼠实验研究;样本量原文未报告;人群:中度TBI小鼠;干预:氨甲环酸1、10、100 mg/kg,氨基己酸400 mg/kg,抑肽酶100 kIU/kg,或等量生理盐水,伤后10分钟给药;主要终点:血清和脑组织炎症因子及30天海马磷酸化tau。
- 氨甲环酸组伤后1小时脑TNF-α降低,24小时脑TNF-α、IL-6、MCP-1较TBI-NS组降低。
- 氨甲环酸组血清TNF-α和MIP-1α在1至24小时较TBI-NS组显著升高。
- 氨甲环酸组磷酸化tau较TBI-NS组呈剂量依赖性显著降低。
- 氨基己酸组伤后1小时脑IL-6升高,24小时血清TNF-α、MIP-1α、MCP-1较TBI-NS组升高。
- 抑肽酶组血清TNF-α、IL-6、MIP-1α在1至24小时升高,脑细胞因子与TBI-NS组无差异。
证据类型、等级与局限
- 证据类型:动物实验(小鼠中度TBI模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,氨甲环酸可能以剂量依赖方式提供急性神经炎症保护。
- 作者认为,氨基己酸在TBI后可能有害,增加脑和全身炎症效应。
- 作者认为,抑肽酶可能增加全身炎症而对神经炎症无显著贡献。
- 作者认为,虽然无抗纤溶药物改善全身炎症,但这些数据提示氨甲环酸可能在TBI后提供最有益的炎症调节。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Administration of antifibrinolytic medications, including tranexamic acid (TXA), may reduce head injury-related mortality. The effect of these medications on post-traumatic brain injury (TBI) inflammatory response is unknown. The goal of this study was to investigate the role of available antifibrinolytic medications on both systemic and cerebral inflammation after TBI.
METHODS: An established murine weight drop model was used to induce a moderate TBI. Mice were administered 1, 10, or 100 mg/kg of TXA, 400 mg/kg of aminocaproic acid (Amicar, Hospira, Lake Forest, IL), 100 kIU/kg of aprotonin, or equivalent volume of normal saline (NS) 10 minutes after recovery. Mice were euthanized at 1, 6, or 24 hours. Serum and cerebral tissue were analyzed for neuron-specific enolase and inflammatory cytokines. Hippocampal histology was evaluated at 30 days for phosphorylated tau accumulation.
RESULTS: One hour after TBI, mice given TXA displayed decreased cerebral cytokine concentrations of tumor necrosis factor α (TNF-α) and, by 24 hours, displayed decreased concentrations of cerebral TNF-α, interleukin (IL)-6, and monocyte chemoattractant protein 1 compared with TBI-NS. However, serum concentrations of TNF-α and macrophage inflammatory protein 1α (MIP-1α) were significantly elevated from 1 to 24 hours in TBI-TXA groups compared with TBI-NS. The concentration of phosphorylated tau was significantly decreased in a dose-dependent manner in TBI-TXA groups compared with TBI-NS. By contrast, Amicar administration increased cerebral cytokine levels of IL-6 1 hour after TBI, with serum elevations noted in TNF-α, MIP-1α, and monocyte chemoattractant protein 1 at 24 hours compared with TBI-NS. Aprotonin administration increased serum TNF-α, IL-6, and MIP-1α from 1 to 24 hours without differences in cerebral cytokines compared with TBI-NS.
CONCLUSION: Tranexamic acid administration may provide acute neuroinflammatory protection in a dose-dependent manner. Amicar administration may be detrimental after TBI with increased cerebral and systemic inflammatory effects. Aprotonin administration may increase systemic inflammation without significant contributions to neuroinflammation. While no antifibrinolytic medication improved systemic inflammation, these data suggest that TXA may provide the most beneficial inflammatory modulation after TBI.
参考来源
- Wallen TE, Singer KE, Baucom MR, et al. Effects of antifibrinolytics on systemic and cerebral inflammation after traumatic brain injury. J Trauma Acute Care Surg. 2022. PMID: 35319541. doi:10.1097/TA.0000000000003607
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。